Literature DB >> 28628391

Interest and Attitudes of Patients With Advanced Cancer With Regard to Secondary Germline Findings From Tumor Genomic Profiling.

Jada G Hamilton1, Elyse Shuk1, Margaux C Genoff1, Vivian M Rodríguez1, Jennifer L Hay1, Kenneth Offit1, Mark E Robson1.   

Abstract

PURPOSE: Tumor genomic profiling (TGP) can reveal secondary findings about inherited disease risks in a patient with cancer. Little is known about how patients with advanced cancer, currently the primary users of TGP, perceive the benefits and harms of secondary germline findings.
METHODS: We conducted semistructured interviews with 40 patients with advanced breast, bladder, colorectal, or lung cancer who had TGP. Qualitative interview data were evaluated by using a thematic content analysis approach.
RESULTS: Most participants expressed interest in the prospect of learning their secondary germline findings (57%), although a minority was equivocal (29%) or disinterested (14%). Reasons for these preferences varied but were influenced by participants' perceptions of diverse benefits and harms of this information, which they regarded as relevant to themselves; their families; and other patients with cancer, medical science, and society. These attitudes were uniquely shaped by participants' personal disease experiences and health status.
CONCLUSION: Many patients with advanced cancer are interested in learning secondary germline findings and hold optimistic and perhaps unrealistic beliefs about the potential health benefits. Patients also have important concerns about clinical and emotional implications of this information. These perceptions are necessary to address to ensure that patients make informed decisions about learning secondary germline findings.

Entities:  

Mesh:

Year:  2017        PMID: 28628391      PMCID: PMC5508446          DOI: 10.1200/JOP.2016.020057

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  27 in total

1.  Disclosing pathogenic genetic variants to research participants: quantifying an emerging ethical responsibility.

Authors:  Christopher A Cassa; Sarah K Savage; Patrick L Taylor; Robert C Green; Amy L McGuire; Kenneth D Mandl
Journal:  Genome Res       Date:  2012-01-06       Impact factor: 9.043

2.  Mandatory extended searches in all genome sequencing: "incidental findings," patient autonomy, and shared decision making.

Authors:  Lainie Friedman Ross; Mark A Rothstein; Ellen Wright Clayton
Journal:  JAMA       Date:  2013-07-24       Impact factor: 56.272

3.  Attitudes of patients with cancer about personalized medicine and somatic genetic testing.

Authors:  Stacy W Gray; Katherine Hicks-Courant; Christopher S Lathan; Levi Garraway; Elyse R Park; Jane C Weeks
Journal:  J Oncol Pract       Date:  2012-08-07       Impact factor: 3.840

4.  Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing.

Authors:  Helen H Won; Sasinya N Scott; A Rose Brannon; Ronak H Shah; Michael F Berger
Journal:  J Vis Exp       Date:  2013-10-18       Impact factor: 1.355

Review 5.  Managing incidental findings in human subjects research: analysis and recommendations.

Authors:  Susan M Wolf; Frances P Lawrenz; Charles A Nelson; Jeffrey P Kahn; Mildred K Cho; Ellen Wright Clayton; Joel G Fletcher; Michael K Georgieff; Dale Hammerschmidt; Kathy Hudson; Judy Illes; Vivek Kapur; Moira A Keane; Barbara A Koenig; Bonnie S Leroy; Elizabeth G McFarland; Jordan Paradise; Lisa S Parker; Sharon F Terry; Brian Van Ness; Benjamin S Wilfond
Journal:  J Law Med Ethics       Date:  2008       Impact factor: 1.718

6.  Attitudes toward molecular testing for personalized cancer therapy.

Authors:  Rafeek A Yusuf; Deevakar Rogith; Shelly R A Hovick; Susan K Peterson; Allison M Burton-Chase; Bryan M Fellman; Yisheng Li; Carolyn McKinney; Elmer V Bernstam; Funda Meric-Bernstam
Journal:  Cancer       Date:  2014-09-10       Impact factor: 6.860

7.  Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.

Authors:  Kasmintan A Schrader; Donavan T Cheng; Vijai Joseph; Meera Prasad; Michael Walsh; Ahmet Zehir; Ai Ni; Tinu Thomas; Ryma Benayed; Asad Ashraf; Annie Lincoln; Maria Arcila; Zsofia Stadler; David Solit; David M Hyman; David Hyman; Liying Zhang; David Klimstra; Marc Ladanyi; Kenneth Offit; Michael Berger; Mark Robson
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

Review 8.  A systematic review of perceived risks, psychological and behavioral impacts of genetic testing.

Authors:  Jodi T Heshka; Crystal Palleschi; Heather Howley; Brenda Wilson; Philip S Wells
Journal:  Genet Med       Date:  2008-01       Impact factor: 8.822

9.  Incidental findings in clinical genomics: a clarification.

Authors: 
Journal:  Genet Med       Date:  2013-07-04       Impact factor: 8.822

10.  Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?

Authors:  Debu Tripathy; Kathleen Harnden; Kimberly Blackwell; Mark Robson
Journal:  BMC Med       Date:  2014-08-12       Impact factor: 8.775

View more
  14 in total

1.  Disclosure of secondary findings in exome sequencing of 2480 Japanese cancer patients.

Authors:  Yasue Horiuchi; Hiroyuki Matsubayashi; Yoshimi Kiyozumi; Seiichiro Nishimura; Satomi Higashigawa; Nobuhiro Kado; Takeshi Nagashima; Maki Mizuguchi; Sumiko Ohnami; Makoto Arai; Kenichi Urakami; Masatoshi Kusuhara; Ken Yamaguchi
Journal:  Hum Genet       Date:  2020-07-24       Impact factor: 4.132

2.  Colorectal Cancer Survivors' Receptivity toward Genomic Testing and Targeted Use of Non-Steroidal Anti-Inflammatory Drugs to Prevent Cancer Recurrence.

Authors:  Denalee M O'Malley; Cindy K Blair; Alissa Greenbaum; Charles L Wiggins; Ashwani Rajput; Vi K Chiu; Anita Y Kinney
Journal:  J Community Genet       Date:  2022-01-08

3.  Engaging Patients in Precision Oncology: Development and Usability of a Web-Based Patient-Facing Genomic Sequencing Report.

Authors:  Ilana B Solomon; Sarah McGraw; Jenny Shen; Adem Albayrak; Gil Alterovitz; Melanie Davies; Catherine Del Vecchio Fitz; Rachel A Freedman; Lisa N Lopez; Lynette M Sholl; Eliezer Van Allen; Joanne Mortimer; Marwan Fakih; Sumanta Pal; Karen L Reckamp; Yuan Yuan; Stacy W Gray
Journal:  JCO Precis Oncol       Date:  2020-04-14

4.  Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.

Authors:  Maria I Carlo; Veda N Giri; Channing J Paller; Wassim Abida; Joshi J Alumkal; Tomasz M Beer; Himisha Beltran; Daniel J George; Elisabeth I Heath; Celestia S Higano; Rana R McKay; Alicia K Morgans; Akash Patnaik; Charles J Ryan; Edward M Schaeffer; Walter M Stadler; Mary-Ellen Taplin; Noah D Kauff; Jacob Vinson; Emmanuel S Antonarakis; Heather H Cheng
Journal:  JCO Precis Oncol       Date:  2018-08-16

5.  Decision-Making Preferences About Secondary Germline Findings That Arise From Tumor Genomic Profiling Among Patients With Advanced Cancers.

Authors:  Jada G Hamilton; Elyse Shuk; Margaux Genoff Garzon; Vivian M Rodríguez; Joy Westerman; Jennifer L Hay; Kenneth Offit; Mark E Robson
Journal:  JCO Precis Oncol       Date:  2017-12-21

6.  Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial.

Authors:  Salma Shickh; Marc Clausen; Chloe Mighton; Mariana Gutierrez Salazar; Kathleen-Rose Zakoor; Rita Kodida; Emma Reble; Christine Elser; Andrea Eisen; Seema Panchal; Melyssa Aronson; Tracy Graham; Susan Randall Armel; Chantal F Morel; Ramzi Fattouh; Emily Glogowski; Kasmintan A Schrader; Jada G Hamilton; Kenneth Offit; Mark Robson; June C Carroll; Wanrudee Isaranuwatchai; Raymond H Kim; Jordan Lerner-Ellis; Kevin E Thorpe; Andreas Laupacis; Yvonne Bombard
Journal:  BMJ Open       Date:  2019-10-07       Impact factor: 2.692

7.  Implementation of Precision Cancer Medicine: Progress and the Path to Realizing the Promise of Tumor Sequencing.

Authors:  Angela R Bradbury
Journal:  J Oncol Pract       Date:  2019-05-21       Impact factor: 3.840

8.  Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening.

Authors:  Kenneth Offit; Kaitlyn A Tkachuk; Zsofia K Stadler; Michael F Walsh; Hector Diaz-Zabala; Jeffrey D Levin; Zoe Steinsnyder; Vignesh Ravichandran; Ravi N Sharaf; Melissa K Frey; Steven M Lipkin; Mark E Robson; Jada G Hamilton; Joseph Vijai; Semanti Mukherjee
Journal:  J Clin Oncol       Date:  2020-01-10       Impact factor: 50.717

9.  Attitudes toward genomic tumor profiling tests in Japan: patients, family members, and the public.

Authors:  Akiko Nagai; Izen Ri; Kaori Muto
Journal:  J Hum Genet       Date:  2019-01-10       Impact factor: 3.172

10.  Genomic Testing for Relapsed and Refractory Lymphoid Cancers: Understanding Patient Values.

Authors:  Sarah Costa; Dean A Regier; Adam J N Raymakers; Samantha Pollard
Journal:  Patient       Date:  2021-03       Impact factor: 3.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.